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Abstract
Objective—The second-generation antipsychotics are associated with metabolic abnormalities in
patients with schizophrenia. Elderly patients with Alzheimer’s disease are frequently treated with
these antipsychotics but there is little data available on their metabolic effects.
Methods—We assessed 186 male and 235 female Alzheimer’s disease outpatients from the
Clinical Antipsychotic Trials of Intervention Effectiveness–Alzheimer’s Disease (CATIE-AD) for
changes in weight, waist circumference, blood pressure, fasting glucose, and lipids in relation to
duration of second-generation antipsychotics (i.e., olanzapine, quetiapine, and risperidone) use
throughout the 36-week trial, using logistic regression and mixed-effects models.
Results—Females showed significant weight gain of 0.14 lb per week of use (p = 0.006) while
change was nonsignificant in males. The odds ratios of significant weight gain (i.e., ≥ 7% of body
weight) compared to patients who did not use antipsychotics were 1.56 (95% CI 0.53 to 4.58),
2.89 (95% CI 0.97 to 8.64), and 3.38 (95% CI 1.24 to 9.23) among patients with antipsychotics
use ≤ 12 weeks, > 12 to 24 weeks, and > 24 weeks during the trial, respectively. Olanzapine and
quetiapine treatments were significantly associated with weight gain (0.12 and 0.14 pounds/week,
respectively). In addition, olanzapine was significantly associated with decreases in HDL
cholesterol (−0.19mG/dL/week), and increased girth (0.07 inches/week) relative to the placebo
group. No treatment effects were noted for changes in blood pressure, glucose, and triglycerides.
Conclusion—Second-generation antipsychotics use was associated with weight gain in females,
with olanzapine and quetiapine in particular, and with unfavorable change in HDL cholesterol and
girth with olanzapine. The potential consequences of these effects suggest that patients with
Alzheimer’s disease treated with second-generation antipsychotics should be monitored closely.
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Neuropsychiatric symptoms are highly prevalent among patients with Alzheimer’s disease 1
and second-generation antipsychotics have been frequently used for their treatment. 2
second-generation antipsychotics, however, especially olanzapine, are associated with
metabolic abnormalities, including weight gain, increased risk for diabetes mellitus, and
worsening lipid profile in patients with schizophrenia. 3-6
The data regarding adverse metabolic effects of second-generation antipsychotics has been
in younger or middle-aged adults and patients with Alzheimer’s disease have not been
systematically assessed. The several randomized, placebo-controlled trials of second-
generation antipsychotics in Alzheimer’s disease and dementia patients, mainly residing in
nursing homes, have not assessed potential metabolic changes and they were not outcomes
of interest. 7, 8 Considering that epidemiology studies indicate that weight, diabetes mellitus,
and dyslipidemia are risk factors for both cardiovascular disease and Alzheimer’s disease, 9,
10 and the established relationships of second-generation antipsychotics use with
cerebrovascular adverse events 11 and deaths 12 in patients with dementia, it is important to
know whether antopsychotic treatment worsens cardiometabolic risks in patients with
Alzheimer’s disease.
The Clinical Antipsychotic Trials of Intervention Effectiveness–Alzheimer’s Disease
(CATIE-AD) employed a unique design, reflecting decisions made in clinical practice, to
compare the effectiveness of three second-generation antipsychotics, olanzapine, quetiapine,
and risperidone, and placebo over 36 weeks for treating delusions and aggression in
outpatients with Alzheimer’s disease and provided well-controlled longitudinal data to
generate hypotheses for future testing. 13 To assess metabolic effects of second-generation




CATIE-AD was a 42-site, multi-center, randomized, double-blind, placebo-controlled trial
designed to examine the effectiveness of second-generation antipsychotics over the course
of 36 weeks in treating psychosis and agitation occurring in outpatients with Alzheimer’s
disease. 13 Briefly, four phases (phase 1, 2, 3, and open-choice phase) were designed to
reflect clinical practice and decisions in prescribing second-generation antipsychotics among
patients. In phase 1, 2, or 3, if a patient did not exhibit efficacy or tolerability at a time after
2 weeks of treatment, study physicians could move the patient to the subsequent phase to
receive a study medication (not placebo) differing from his/her previous treatments.
In phase 1, a total of 421 eligible patients were randomized in a double-blind fashion to the
olanzapine, quetiapine, risperidone, or placebo groups in a 2:2:2:3 ratio. After
randomization, clinic visits occurred at weeks 2, 4, 8, 12, 24, and 36. Patients doing well on
assigned treatment continued on phase 1 treatment throughout the trial. Patients who
discontinued their phase 1 treatments were double-blindly randomized to one of the
antipsychotics or the antidepressant citalopram in phase 2. Patients who discontinued from
phase 2 and entered phase 3 received randomly assigned, open-label study medications that
were not previously prescribed. A patient could also directly shift from any of the three
phases to the open-choice phase to receive non-study medications of the study physician’s
choice. The length of phases 1, 2, 3 and open-choice could range from 2-36, 2-34, 2-32, and
2-34 weeks, respectively. The primary study end point was the time until discontinuation of
treatment for any reason in phase 1. 14 The Institutional Review Board of each site approved
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the study and all subjects or their legally authorized representatives provided written
informed consent.
Current study
The current study assessed the effects of second-generation antipsychotics on metabolic
factors by a prospective analysis of the CATIE-AD trial. A total of 421 subjects (186 men,
235 women) who had a baseline and at least one post-baseline measure of metabolic factors
were included. Changes in weight and other metabolic measures from baseline to the last
observation were outcomes in the analysis (see below). 3 The duration of each second-
generation antipsychotic treatment and the total duration of any second-generation
antipsychotic treatment during follow-up were the exposures of interest. Analyses were
conducted regardless of phase and the order of treatments unless otherwise specified.
Clinical data collection
Participants’ age, gender, ethnicity, and years of education were obtained. Height, weight,
blood pressure, waist, and hip circumference were measured at baseline and at each clinic
visit during the trial. Body mass index (BMI, calculated as weight (kilograms)/height
(meters2)) and waist-hip-ratio were derived from these data. Blood pressure was measured
once in a seated position at each visit.
Laboratory measurements
Blood samples were obtained at baseline and at weeks 12, 24, and 36 during the trial
(regardless of phases). Serum glucose assays and plasma total cholesterol, triglyceride, and
high-density lipoprotein (HDL) cholesterol assays were performed by Quintiles central
laboratory using standard methods, and low-density lipoprotein (LDL) cholesterol was
estimated using the Friedewald equation. The time from the last meal to the blood draw
varied among patients and we defined those blood samples obtained at least 8 hours since
the last meal as fasting samples. 15
Duration of study medication use
The start and end dates of each second-generation antipsychotic and placebo treatment were
recorded for every patient. The duration of olanzapine, quetiapine, risperidone, or placebo
use was calculated as the time interval between the start and end dates regardless of phase.
For example, if a patient reached phase 3 at the end of the trial then the patient had switched
treatment twice after the initial randomized assignment. Thus, the patient could have three
duration variables to reflect the length of exposure to each second-generation antipsychotic
or placebo administered during the trial. The period during which a patient received placebo,
citalopram, or open-choice antipsychotic medications other than the second-generation
antipsychotics did not contribute to the duration calculations for antipsychotic use.
Non-study medication use
The use of non-study medications including antihypertensive, lipid-modifying, and
antidiabetic medications was assessed at each visit and recorded on medication record forms
that included dose, frequency and dates of use.
Statistical analysis
Analysis of change in metabolic measures from baseline to the last observation was
performed for all subjects who had baseline and at least one follow-up metabolic measure.
Separate general linear regression models were fitted for each metabolic factor including
weight, waist circumference, systolic blood pressure (SBP), diastolic blood pressure (DBP),
HDL cholesterol, fasting glucose, and fasting triglycerides. The change in each metabolic
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factor from baseline to last observation was the dependent variable. Cumulative duration of
any second-generation antipsychotics use was the primary independent variable. The
regression coefficient associated with duration represents the change in the metabolic factor
per week of antipsychotic use. Differences in this duration regression coefficient by gender,
age group (≥ 80 vs < 80 y), and baseline BMI (BMI < 25 kg/m2, 25 ≤ BMI < 30 kg/m2,
BMI ≥ 30 kg/m2) were tested for significance by including duration × gender, duration ×
age group, and duration × baseline BMI interaction terms.
Logistic regression was used to examine whether longer cumulative duration of second-
generation antipsychotics use increases the likelihood of having clinically significant weight
gain, as commonly defined as at least 7% increase from baseline. The binary dependent
variable was categorized percentage weight gain (< 7% and ≥ 7%). The independent
variable was categorized cumulative duration of antipsychotic use (none, 1 day to 12 weeks,
> 12 to 24 weeks, and > 24 to 36 weeks). Age and gender were included in the model as
covariates.
With regard to the effects of individual antipsychotic treatment on metabolic measures, we
evaluated weekly rate of change in metabolic measures by initial randomized groups (the
olanzapine, quetiapine, risperidone, or placebo groups). All available follow-up visits in
phase 1 were included for each subject in order to assess the effects of each individual
medication treatment. Analyses of triglyceride and glucose were restricted to fasting
samples and subjects whose glucose concentrations were less than 100 mg/dL with unknown
fasting status. In a mixed-effects model, a metabolic factor at a given follow-up time was
regressed on time since randomization (random effect), and the randomized group was
modeled as a fixed effect. The main effect of treatment group examined the group difference
of each metabolic measure at baseline, while the group × time interaction term tested
whether the weekly rate of change in each metabolic measure differed across groups. Age
and gender were included as covariates to control for potential confounding effects.
Study site was not used as a covariate because an unconditional means models for each
metabolic factor 16 indicated that the changes in metabolic factors did not significantly
cluster by sites. (The proportion of the total co-variance between sites ranged from 0.004 to
0.039 compared to the sum of between- and within-site covariance).
All analyses were conducted using Statistical Analysis System version 9.1 software (SAS
Institute, Cary, NC). Statistical significance was accepted at two-sided p < 0.05.
Results
Baseline sample characteristics
A total of 421 patients with Alzheimer’s disease were randomized to four groups
(olanzapine, quetiapine, risperidone, or placebo). We summarized the demographic,
cognitive, and metabolic characteristics at randomization in Table 1. There were no
significant differences in baseline characteristics among randomized groups except for mean
systolic blood pressure (p = 0.02). The mean age at randomization was 77.9 years (range 51
to 103 years). Fifty-six percent were female, 21% were non-Caucasian, and 59% were
married. On average, patients were overweight and had elevated SBP. Almost half of the
subjects (46%) were using antihypertensive agents, 60% cholinesterase inhibitor or
memantine anti-dementia medications, 24% cholesterol and triglyceride reducers, and 10%
oral blood glucose lowering medications at randomization. Table 1 also includes the number
of subjects reaching specific trial phases by weeks 12, 24, and 36.
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Cumulative duration of total second-generation antipsychotic use
During the trial, 349 (83%) subjects received second-generation antipsychotics for at least
one day. Seventy-two subjects (17%) out of a total sample of 421 had no exposure to
second-generation antipsychotics because they received placebo, citalopram, or open-choice
antipsychotic medications other than the study medications. The cumulative duration of
antipsychotic use ranged from 0 to 46 weeks with a median of 12.1 weeks. Among subjects
who received antipsychotics for at least one day (N = 349), 73 (21%), 63 (18%), and 61
(17%) subjects were on olanzapine, quetiapine, and risperidone alone, respectively. Forty-
three (12%) subjects had olanzapine and quetiapine, 42 (12%) olanzapine and risperidone,
43 (12%) quetiapine and risperidone, and 24 (7%) had all three second-generation
antipsychotics at some time during the trial follow-up.
Weight gain and duration of antipsychotic use
Among 418 subjects with weight measurements available at both randomization and end of
trial, duration of antipsychotic use was statistically significantly associated with weight gain
after adjustment for age (p = 0.02) (Figure 1). As the primary independent variable in the
general linear regression model, 71 of 418 subjects had no exposure (cumulative duration of
zero) to second generation antipsychotics. These subjects with no SGA exposure were
included in the model as the reference group. The regression coefficient associated with
duration represents the additional weight change per week of antipsychotic use beyond the
weight change experienced in the unexposed group. A significant interaction between
duration of antipsychotic use and gender was found (p = 0.008). In the overall sample,
average weight gain was 0.08 pounds per week of antipsychotic use (SE = 0.03). Female
subjects showed a statistically significant weight gain of 0.14 pounds per week of
antipsychotic use (SE = 0.04, p = 0.006) while the change in weight in males was −0.02
pounds per week of antipsychotic use (SE = 0.04, p = 0.64). No significant interaction
between duration of antipsychotic use and age group (≥ 80 vs < 80 yrs) was noted (p =
0.45).
Similarly, duration of antipsychotic use was associated with increase in BMI after
adjustment for age (0.02 kg/m2 per week of antipsychotic use, p = 0.006), with a significant
interaction between duration of antipsychotic use and gender (p = 0.005). Females showed a
significant increase in BMI of 0.03 kg/m2 per week of antipsychotic use (p = 0.004) while
males did not (−0.003 kg/m2 per week of antipsychotic use, p = 0.64).
To examine whether the association between weight gain and duration of antipsychotic use
was influenced by baseline BMI, we tested the interaction term duration × baseline BMI.
Because only 14 patients (5 men and 9 women) were underweight at baseline (i.e., BMI < 20
kg/m2) we created three categories of baseline BMI: under + normal weight (BMI < 25 kg/
m2), overweight (25 ≤ BMI < 30 kg/m2), and obese (BMI ≥ 30 kg/m2). There were 125, 69,
38 females, and 81, 75, and 24 males in each of the categories, respectively. No evidence of
effect modification by baseline BMI was found (duration × baseline BMI, p = 0.93), nor
when we further tested whether baseline BMI modifies the influence of gender on weight
gain per week of antipsychotic use using a 3-way interaction term (duration × gender ×
baseline BMI) (p = 0.43)
Clinically significant weight gain and duration of second-generation antipsychotic use
The duration-dependent association between antipsychotic use and clinically significant
weight gain is presented in Figure 2. Compared to subjects with no use, subjects with at least
24 weeks of antipsychotic use were more likely to have clinically significant weight gain
defined as at least 7% increase from baseline (age- and gender-adjusted odds ratio = 3.38,
95% CI 1.24 to 9.23, p = 0.02). Female gender had a marginally increased likelihood for
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significant weight gain than males (Odds Ratio = 1.79, 95%CI (0.998, 3.211), p = 0.051)
with no significant interaction between duration of antipsychotic use and gender (p = 0.89).
Second-generation antipsychotic treatment interruption
We modeled duration of any second-generation antipsychotic treatment as a continuous
exposure in the above analysis. For patients who remained in phase 1 throughout the trial, or
those who switched from one antipsychotic to another across phases, the duration variable
reflects the treatment exposure without interruption. When a patient was randomly assigned
to a second-generation antipsychotic in phase 1, then to citalopram in phase 2, and switched
to another antipsychotic in phase 3, a gap between antipsychotic treatments occurred that
might dilute the effects of treatment. Only 22 participants of a total of 83 randomized to
citalopram in phase 2 experienced gaps between second-generation antipsychotic treatments,
i.e. received one second-generation antipsychotic in phase 1, citalopram in phase 2, and
another second-generation antipsychotic in phase 3. The mean (SD) duration of citalopram
use among these 22 participants was 9.7 (6.0) weeks, ranging from 1.1 to 21.4 weeks. To
rule out the effect of treatment interruption, we further tested the association between weight
gain and duration of any second-generation antipsychotic excluding these 22 participants
and the results were not altered.
Effects of individual second-generation antipsychotic treatment
The effects of each antipsychotic treatment on the weekly rate of changes in metabolic
measures are summarized in Table 2. For each participant, all available follow-up visits in
phase 1 were included in this analysis. Multivariate mixed effects models were fitted to
evaluate the weekly rate of change of each metabolic measure in relation to the treatment
groups with adjustment for age and gender. At randomization, none of the metabolic
measures differed among groups. Longitudinally, when compared to the placebo group,
significant average weekly weight gain was observed in the olanzapine and quetiapine
groups (0.12 pounds/week, SE = 0.06, p = 0.03 and 0.14 pounds/week, SE = 0.06, p = 0.02),
and was marginally significant in the risperidone group (0.10 pounds/week, SE = 0.06, p =
0.07). Similar patterns of BMI change were apparent among the three antipsychotic
treatments. In addition, olanzapine treatment was significantly associated with increased
waist circumference (0.07 inches/week, SE = 0.02, p = 0.004) and decreased HDL
cholesterol (−0.19 mG/dL/week, SE = 0.07, p = 0.004). No effects of antipsychotic
treatment were noted for changes in systolic and diastolic BP, glucose, and triglycerides.
Discussion
Clinically significant weight gain, increasing with duration of use, is associated with
atypical antipsychotic treatment among outpatients with Alzheimer’s disease. Additionally,
an increase in waist circumference and decrease in HDL cholesterol is associated with
olanzapine. The relationship of the weight gain to duration of treatment and a gender
interaction makes this observation particularly compelling.
The rate of weight gain was 0.10 - 0.14 pounds/week and the magnitude of the gain was 1.4,
1.7, and 1.2 pounds after 12 weeks for olanzapine, quetiapine, and risperidone, respectively.
Weight gain in older people cannot be viewed as a positive event unless it is due to
increased lean muscle mass which was unlikely to have occurred in this study that did not
include a physical training intervention and observed increased waist girth. Visceral
adiposity is associated with greater risks of insulin resistance, dyslipidemia, and glucose
intolerance, and must be considered as an adverse effect rather than a benefit in these
individuals.
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Most data regarding adverse metabolic effects of second-generation antipsychotics has been
in younger or middle-aged adults. The magnitude of the weight gain, increase in waist
circumference, and change in HDL cholesterol reported in Alzheimer’s disease patients is
similar to that reported from a large randomized trial in younger people with schizophrenia
(mean age 41 years, 74% male, and mean BMI 30 kg/m2), 5, 6 although Alzheimer’s disease
patients had substantially lower BMI, narrower girths, and higher HDL cholesterol levels at
baseline.
In the few randomized, placebo-controlled trials in Alzheimer’s disease and other dementia
patients, the associations between antipsychotic use and weight change were inconsistent or
not adequately reported. Although olanzapine was associated with about a 1.0 kg increase
and a higher incidence of significant weight gain compared to risperidone and placebo in
one 10-week outpatient trial, 17 in a 26-week trial in outpatients with mild to moderate
Alzheimer’s disease but without agitation or psychotic symptoms, a mean 1.4 kg increase in
weight was not significantly greater than the placebo group. 18 Similarly, increased weight
of about 1.0 kg was associated with olanzapine in one nursing home trial 19 but not in
another. 20 Two 10-week long quetiapine trials in dementia patients in nursing homes did
not report significant differences in weight change between the treatment and placebo
groups, 21, 22 Three of four risperidone trials 7 did not address 23 or did not report changes in
weight, BMI, or other metabolic measures. 24, 25 The one trial that stated there was a
significant increase in weight with risperidone compared to placebo provided no details. 26
By comparison, we found significantly greater weight gain in olanzapine- and quetiapine-
treated patients compared to placebo and a statistical trend for risperidone.
Females showed significant weight gain associated with antipsychotic treatment, while
males did not. Females were older than males (mean age 78.6 (7.8) vs. 76.8 (6.9) years,
respectively, p = 0.015) and had higher HDL cholesterol (58.5 (15.2) vs. 47.1 (14.2) mg/dL,
p < 0.0001). At baseline, males and females were similar with regard to cognitive function,
years of education, BMI, blood pressure, fasting glucose and triglyceride levels. Because
elderly females proportionally have more fat mass and less lean body mass than elderly
males, they may be more susceptible to second-generation antipsychotic-associated weight
gain. The difference in weight changes between females and males observed here was not
reported in other studies among Alzheimer’s disease patients or the elderly and warrants
further examination.
Importantly, we observed an increasing difference in actual weight gain with continuing
antipsychotic treatment over the 36-week trial. The prevalence of significant weight gain
was 10%, 17%, and 20% among patients with less than 12 weeks, 12-24 weeks, and greater
than 24 weeks of use compared to 7% with no use. This is particularly concerning given the
association of weight gain with both cerebrovascular disease morbidity and mortality, both
of which appear independently associated with antipsychotic use in dementia patients and
are listed as warnings in the drugs’ labeling. Increased risk of second-generation
antipsychotic-associated cerebrovascular adverse events is evident among patients with
dementia. 11 We previously reported increased risks for death with second-generation
antipsychotics compared to placebo treatment in 15 randomized, placebo-controlled trials. 12
Although some patients in the current trial may have benefited clinically from antipsychotic
use in terms of particular symptom reduction (e.g., anger, aggression, and paranoid ideas),
they did not benefit in performance of activities of daily living, care needs, or quality of life.
27 Considered together, the risks of adverse events associated with longer term use of
second-generation antipsychotics must be carefully balanced against their benefits. 7, 8, 12,
14, 27
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There are several limitations to the present study. First, the design of CATIE-AD did not
allow for a parallel group comparison over 36 weeks of all patients randomized to their
original (phase 1) treatment. The number of patients treated continuously with one
antipsychotic over the entire trial was small (N = 78), representing persons who were
responding to and tolerating their initially randomized medication or placebo. Secondly,
incomplete laboratory data due to non-fasting blood samples and 12-week assessment
intervals decreased the sample size and power to assess changes in fasting glucose and
triglycerides. Thirdly, we were not able to address a potential dose effect due to the flexible
dosing design. Average doses, however, in both phases 1 and 2 were from 5.5 to 5.6, 56.5 to
61.1, and 1.0 to 1.1 mg/day for olanzapine, quetiapine, and risperidone, respectively. 14
These doses were generally lower than other Alzheimer’s disease trials and considerably
lower than doses used to treat schizophrenia or in the CATIE-Schizophrenia trial.5
In summary, about 20% of outpatients with Alzheimer’s disease developed significant
weight gain increasing over 36 weeks with antipsychotic treatment. Patients treated with
olanzapine in particular showed unfavorable changes in HDL cholesterol and abdominal
girth. These are additional risks to consider when initiating and continuing antipsychotic
therapy in individuals with Alzheimer’s disease. Clinical trials of the atypical antipsychotics
have shown modest efficacy compared to placebo in improving behavioral symptoms but
adverse effects limit their overall effectiveness. 14, 27 Alzheimer’s disease patients treated
with second-generation antipsychotics should be monitored closely.
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Age-adjusted weight change (in pounds, +/− one standard error) per week of cumulative
second-generation antipsychotic (SGA) use beyond that experienced in the no SGA use
group. Data are presented in the overall sample and stratified by gender (N = 418). An
additional average weight gain of 0.08 (SE = 0.03) pounds per week of SGA use was
observed in the overall sample (p = 0.02). There was a significant interaction between
duration of SGA use and gender (p = 0.008).
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Odds ratio (+/− one standard error) of clinically significant weight gain (i.e., ≥ 7%) by
cumulative duration of second-generation antipsychotics (SGA) use with adjustment for age
at randomization and gender (N = 418). SGA use is associated with increased risk for
clinically significant weight gain (≥ 7%) in a duration-dependent manner (p for trend =
0.03). Compared to patients with no SGA use, the odds ratios were: 1.56 (95% CI 0.53 to
4.58, p = 0.42) among patients with SGA use ≤ 12 weeks; 2.89 (95% CI 0.97 to 8.64, p =
0.06) among patients with SGA use between 12 to 24 weeks; 3.38 (95% CI 1.24 to 9.23, p =
0.02) among patients with SGA use more than 24 weeks during the trial. The prevalence of
clinically significant weight gain was 7%, 10%, 17%, and 20% among patients with no SGA
use, SGA use ≤ 12, 12-24, and > 24 weeks, respectively.
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